profile

Miraki23 LLP

A QA Manager Is Chasing a Signature Right Now. It's the 34th of 47 Handoffs Before This CAPA Closes.


The Architecture Brief — Life Sciences Edition | Miraki23 LLP
Life Sciences Edition
The Architecture Brief
August 11, 2026
 
Editorial Statement

Somewhere in a mid-market pharmaceutical company right now, a Quality Assurance manager is chasing a signature. Not electronically. In person, or by email, or by walking a physical folder from one department head's desk to another's, because the CAPA — the Corrective and Preventive Action record that exists to prove the company caught a quality problem and fixed it properly — cannot close without that signature, and the signature cannot happen until three prior approvals have already happened, each one dependent on someone checking an inbox, printing a form, or remembering to forward an attachment.

This is not a hypothetical. It is the operating reality inside more than 40% of mid-market pharma companies across India and APAC today. We call it a Quality Management System. It is more accurately described as an email chain with a filing cabinet attached — and it is, without exaggeration, the highest-risk manual process most pharmaceutical companies are running. Not the manufacturing line. Not the cold chain. The paperwork behind the paperwork: the audit trail an FDA investigator will ask to see, with sixty days' notice or none at all.

This week we go inside Layer 3 of the Pharmaceutical Digital Capability Framework — Manufacturing & Supply Operations — and its direct dependency on Layer 8, Cybersecurity & Digital Trust. Together they answer the question every pharma CIO should be asking before the next inspection notice arrives, not after: is our audit trail a system, or is it a story we tell an investigator and hope holds together?

— Editorial Team  ·  Miraki23 LLP
Story of the Week
Life Sciences · Quality Management · GxP Compliance

Quality Compliance Is Your Highest-Risk Manual Process

Your Quality Management System runs on email chains, PDF sign-offs, and shared drives. Every CAPA takes 47 manual handoffs before closure. An FDA investigator is coming in 60 days. How confident are you in your audit trail?

The CAPA Lifecycle, On Paper, in 2024

Picture the full path of a single Corrective and Preventive Action record: a deviation is logged by hand. An email routes it to a QA reviewer. The reviewer prints it, annotates it, scans it back. It is emailed to the department head for root cause review. That review happens in a meeting with no recorded minutes, summarised afterward in a Word document. The CAPA plan is drafted, routed for approval via three more email threads, revised twice, then walked physically to two signatories whose calendars rarely align in the same building. Effectiveness verification happens weeks later, tracked in a separate spreadsheet nobody else can see. Closure requires a final signature that depends on all of the above having occurred, in order, without a single dropped thread.

Count the handoffs. It is 47. Every one of them is a place where the audit trail can break, where "who approved this and when" becomes a question nobody can answer with certainty — which is precisely the question an FDA investigator is trained to ask first.

GxP compliance — spanning GMP, GCP, and GLP — is not a documentation preference. It is a regulatory requirement for an end-to-end electronic quality management system with complete audit trails, electronic signatures compliant with 21 CFR Part 11 and EU Annex 11, and automated CAPA escalation that does not depend on any single individual remembering to forward an email. Veeva Vault QMS and MasterControl are the industry standards precisely because they replace the 47-handoff paper-and-email chain with a governed digital workflow: every action timestamped, every signature cryptographically bound to the record, every escalation automatic when a deadline is missed rather than dependent on someone noticing.

47
Manual Handoffs per CAPA
40%+
Mid-Market Pharma on Hybrid Paper-Digital QMS
38%
Of FDA Warning Letters Cite Data Integrity
The Regulatory Evidence

The FDA's 2024 inspection data shows that data integrity violations — largely rooted in inadequate electronic records and audit trail systems — remain the single most cited category in Warning Letters, accounting for 38% of all findings.

— FDA Warning Letter Data Analysis, 2024 Annual Report

This is not a statistic to note in passing. It is the single most predictable finding in a modern FDA inspection, and it is almost entirely preventable through system design. An electronic QMS does not merely digitise the 47 handoffs — it collapses most of them. Automated routing replaces manual forwarding. Electronic signatures replace physical walk-arounds. Automated escalation replaces the QA manager who has to remember to chase a stalled approval. The audit trail is not reconstructed after the fact from email search — it exists, complete and query-ready, the moment the investigator asks for it.

Audit-readiness is a system design decision, not a last-minute preparation. The organisations that pass FDA inspections calmly are not the ones that assembled a war room sixty days before the investigator arrived. They are the ones whose QMS was built, from the beginning, to be inspection-ready every single day — because the architecture made non-compliance structurally difficult, not because someone worked a stressful weekend pulling records together.

QMS Audit-Readiness Assessment — Complimentary

An FDA investigator does not schedule around your convenience. Start the assessment now — before the sixty-day notice arrives, not after.

Start the Assessment →
Pharma Digital Capability Framework
Pharmaceutical Digital Capability Framework · Layer 3 + Layer 8
Manufacturing & Supply Operations + Cybersecurity & Digital Trust
9 Layers  ·  36 Domains  ·  ~200 Capabilities  ·  Sandeep Bansal, 2026

Manufacturing transformation — described under the Pharma 4.0 paradigm — is one of the most capital-intensive and compliance-sensitive domains in the pharmaceutical enterprise. Digital manufacturing platforms improve traceability, quality assurance, and regulatory compliance while enabling real-time operational intelligence. Layer 3 is where this week's story lives operationally. Layer 8 is what makes it trustworthy.

Layer 3 · Manufacturing & Supply Operations — Five Domains
Quality Management ★ This Week's Focus

Quality event management, CAPA management, deviation handling, audit management, supplier quality oversight.

Batch Manufacturing Systems

Manufacturing execution systems, batch record management, process analytical technology, equipment integration, OEE monitoring.

Serialization & Packaging

Track-and-trace compliance, aggregation management, packaging artwork management, label verification.

Supply Chain Planning

Demand forecasting, inventory optimization, integrated S&OP, supplier collaboration, capacity planning.

Global Distribution

Cold chain monitoring, distribution network management, import/export compliance, third-party logistics management.

Layer 8 · Cybersecurity & Digital Trust — Five Domains

Pharmaceutical organisations manage some of the most sensitive data in the global economy — clinical trial data, patient health information, proprietary research, and commercially sensitive intelligence. Layer 8 addresses the full spectrum of capabilities required to protect this data, maintain regulatory compliance with data protection frameworks, and preserve organisational trust. It is the layer that makes a QMS audit trail cryptographically defensible, not merely digitally convenient.

Identity & Access Management

Single sign-on, multi-factor authentication, privileged access management, identity governance and administration — the layer that makes every electronic signature attributable to a real, verified individual.

Security Operations

Security information and event management, threat detection and response, vulnerability management, penetration testing.

Data Protection

Data loss prevention, encryption management, privacy impact assessments, GDPR and CCPA compliance.

IP & Research Data Security

Trade secret protection, research data security, clinical data encryption, secure collaboration platforms.

Third-Party Risk Management

Vendor security assessments, supply chain security, partner access governance, third-party monitoring.

Map Your Layer 3 + Layer 8 Maturity →
Miraki23 Perspective

“An audit trail you have to reconstruct is not an audit trail. It is a research project with a regulatory deadline. The companies that pass FDA inspections without a war room are the ones who stopped treating compliance as a sprint and started treating it as an architecture.”

Aparna Bansal  ·  Founder, Miraki23 LLP
Next Week

Your SAP IBP licence cost ₹4 crore. Your demand planners are still overriding 60% of system outputs with Excel models built in 2019. You did not have a technology problem.

Subscribe to the Newsletter

The Architecture Brief — Every Week

GxP compliance, pharma digital architecture, AI governance, higher education transformation, GCC strategy, and enterprise advisory — weekly, for leaders who build, not just manage.

Subscribe Free →
Share on LinkedIn

Know a Pharma CIO or QA Head Who Needs This?

Share this issue with a Quality leader still chasing signatures through email, or a CIO who has sixty days until the next inspection notice. This one is worth the forward.

Share on LinkedIn →
Topics This Week
#QualityManagement #GMP #FDACompliance #PharmaCIO #DataIntegrity #GxPCompliance #21CFRPart11 #CAPA #VeevaVault #PharmaDigitalTransformation #LifeSciences #DigitalTrust #Miraki23

Miraki23 LLP

We help organizations move from fragmented initiatives to structured transformation. At Miraki23, we integrate strategy, digital ecosystems, and performance architecture to deliver measurable business impact.

Share this page